Synairgen plc (SNG.L) Research

Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.

Market snapshot

Symbol
SNG.L
Price
$0.95
Day change
0.00%
Market cap
$11.6M
P/E ratio
-0.23x
52-week range
0.602-10
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Advanced Oncotherapy plc (AVO.L)
  • BiVictriX Therapeutics Plc (BVX.L)
  • Celadon Pharmaceuticals Plc (CEL.L)
  • Destiny Pharma plc (DEST.L)
  • Induction Healthcare Group PLC (INHC.L)
  • MGC Pharmaceuticals Limited (MXC.L)
  • NetScientific plc (NSCI.L)
  • ReNeuron Group plc (RENE.L)

Open Synairgen plc (SNG.L) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.